CINCINNATI, OH--(Marketwire - March 06, 2012) -
Medpace, Inc. today announced the opening of a new fully-staffed, clinical operations office in Lyon, France. This addition brings the total number of Medpace offices across Europe to eleven. The office will be led by Patrick Winkler, MBA, MS, Medpace Country Manager, France.
The Medpace France location will provide full service capabilities across Europe integrating global studies. The office -- located at: 55 rue Baraban, 69003 Lyon, France -- will house regional project study managers, and clinical research associates who have the ability to monitor studies through-out Europe.
The addition of these clinical experts and the new office will support an expansive Medpace European group delivering therapeutic study direction, full-service monitoring, and trial management services in tandem with existing European offices. The office in Lyon becomes part of a global network of clinical operations experts with the ability to conduct Phase I-IV studies, integrating early phase capabilities from Belgium, regulatory expertise from Germany, and safety expertise from Scotland. Medpace continues to invest in Europe, supporting strategic partnerships with existing and new global sponsors.
Medpace is known for therapeutically focused, innovative clinical study design with particular emphasis on oncology, cardiology, metabolic disorders, infectious disease, and CNS.
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.
With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from imaging services (Imagepace), and medical device development from Medpace Medical Device.
Visit the Medpace website at www.medpace.com